Author:
O'Connor Brigid M.,Webber Stephanie,Jackson Robert C.,Galivan John,Rhee Myung S.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference36 articles.
1. Bassendine MF, Curtin NJ, Loose H, Harris AL, James OFW (1987) Induction of remission to hepatocellular carcinoma with a new thymidylate synthase inhibitor CB3717: a phase II study. J Hepatol 4:349
2. Berman EM, Werbel LM (1991) The renewed potential for folate antagonists in contemporary cancer chemotherapy. J Med Chem 34:479
3. Bisset GMF, Jackman AL, O'Connor BM, Jones TR, Calvert AH, Hughes LR (1989) Synthesis of lipophilic analogues of 2-desamino-2-CH3N10-propargyl-5,8-dideazafolate targeted at the enzyme thymidylate synthase (TS). In: Curtis H-CH, Ghisla S, Blau N (eds) Chemistry and biology of pteridines. Walter de Gruyter, Berlin, p 114
4. Cadman E, Benz C, Heimer R, O'Shaughnessy J (1981) Effect of de novo purine synthesis inhibitors on 5-fluorouracil metabolism and cytotoxicity. Biochem Pharmacol 30:2469
5. Calvert AH, Alison DL, Harland SJ, Robinson BA, Jackman AL, Jones TR, Newell DR, Siddik ZH, Wiltshaw E, McElwain TJ, Smith TE, Harrap KR (1986) A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor,N 10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol 4:1245
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献